Investment Team

Stefan founded PE Group in 2006 and brings over 30 years of experience in corporate law, audit, M&A, investment banking and private equity. His career spans KPMG, Linklaters, the Belgian Corporation for International Investment, and Beluga (Euronext Brussels). He has been an investor and board member across more than 20 listed and private companies in Belgium, including UnifiedPost Group, Axiles Bionics, NRG Fitness and Hyloris Pharmaceuticals. Stefan holds Masters degrees in Law and Business Administration from VUB, ULB Solvay Business School, and the University of Chicago (BAEF Fellow).

Stijn is a partner and reference shareholder of PE Group, and brings over 20 years of experience as a serial entrepreneur and CEO in the pharmaceutical industry. He co-founded Hyloris Pharmaceuticals (Euronext Brussels), and previously served as CEO of Alter Pharma and co-CEO of Uteron Pharma, and as CFO then CEO of Docpharma. He also serves as chairman of Exo Biologics and holds multiple non-executive board positions across the biotech sector. Stijn holds a Master's degree in Applied Economics from the University of Antwerp.

Julien joined PE Group as a Senior Investment Associate, where he leads deal analysis, financial due diligence and portfolio company support across sectors including FinTech, healthcare and B2B services. He is actively involved in managing current investments such as Axiles Bionics, UnifiedPost Group, TRAINM and NRG Fitness. Alongside his role at PE Group, Julien is co-founder and CEO of Stolp, a digital wellbeing startup developing Faraday cage devices to help people disconnect from their smartphones. He holds a Master's degree in Business Engineering and brings a hands-on, entrepreneur-first investment mindset to every engagement.

Pieter is a partner and shareholder at PE Group, representing the Van Rompay family — one of Belgium's most prominent pharma entrepreneurial dynasties behind Docpharma, Uteron Pharma, Alter Pharma and Hyloris Pharmaceuticals. He holds multiple board mandates in the pharmaceutical and biotech sector, including at Biogenosis, the family's pharma investment vehicle. Pieter brings deep networks and strategic insight rooted in decades of family involvement across private equity and life sciences in Belgium. His involvement ensures continuity of long-term, patient capital aligned with PE Group's entrepreneurial investment philosophy.